Biomica (Israel)

We are pleased to announce that Biomica, a subsidiary of Evogene, has entered into an exclusive worldwide licensing agreement with Lishan Biotech for BMC128, a microbiome-based therapeutic for renal and lung cancer that has successfully completed its Phase 1 clinical trial. As part of this transition, the Biomica website is no longer active. For more information, please visit www.

Basic Information

Documented Facts

Evidence and Sources

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Biomica (Israel).

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

We are pleased to announce that Biomica, a subsidiary of Evogene, has entered into an exclusive worldwide licensing agreement with Lishan Biotech for BMC128, a microbiome-based therapeutic for renal and lung cancer that has successfully completed its Phase 1 clinical trial. As part of this transition, the Biomica website is no longer active. For more information, please visit www.

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.